ArticleMikrochimica acta2025
Molecularly imprinted polymer modified g-C
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To enable rapid, on-site monitoring of amoxicillin and ensure controlled administration, we have developed a paper-based analytical device (PAD) incorporating a molecularly imprinted polymer (MIP) anchored on graphitic carbon nitride (g-C₃N₄) nanosheets. The MIP@g-C₃N₄ composite was synthesized via in situ polymerization of 3-aminopropyl triethoxysilane (APTES) and tetraethyl orthosilicate (TEOS) around amoxicillin templates on g-C₃N₄, yielding highly specific binding cavities upon template removal. The g-C₃N₄ nanozyme's intrinsic peroxidase-like activity catalyzes the oxidation of colorless 3,3',5,5'-tetramethylbenzidine (TMB) to its blue oxidized form (oxTMB) in the presence of hydrogen peroxide. In the absence of amoxicillin, a vivid blue signal develops, whereas competitive binding of amoxicillin at the MIP sites inhibits nanozyme activity, causing a proportional decrease in color intensity. Analytical characterization demonstrated a linear response over 0-100 µM amoxicillin, with a limit of detection (LOD) of 0.97 µM. The integration with the PAD format permits semi-quantitative visual readout and quantitative determination via a portable smartphone, all within minutes and without the need for complex instrumentation. When applied to spiked milk and tap water, the MIP@g-C₃N₄ sensor achieved recoveries of 92-105% with negligible interference from structurally related antibiotics. The marriage of MIP selectivity, g-C₃N₄ nanozyme catalysis, and low-cost PAD architecture delivers a user-friendly, field-deployable platform for rapid amoxicillin screening, promising significant potential to bolster antibiotic stewardship and mitigate overdose-related health risks across clinical, environmental, and food-safety applications.
Indexed as
Identifiers
41247386What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.